Neurocrine Biosciences
NBIX
NBIX
212 hedge funds and large institutions have $3.44B invested in Neurocrine Biosciences in 2016 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 85 increasing their positions, 75 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
3% less funds holding
Funds holding: 218 → 212 (-6)
27% less capital invested
Capital invested by funds: $4.7B → $3.44B (-$1.26B)
Holders
212
Holding in Top 10
9
Calls
$22.7M
Puts
$16.2M
Top Buyers
| 1 | +$48.8M | |
| 2 | +$28.7M | |
| 3 | +$26.8M | |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$25.2M |
| 5 |
Goldman Sachs
New York
|
+$22.7M |
Top Sellers
| 1 | -$33.1M | |
| 2 | -$29.7M | |
| 3 | -$23.7M | |
| 4 |
CCI
Columbus Circle Investors
|
-$18.2M |
| 5 |
VAM
Visium Asset Management
New York
|
-$13.4M |